Kailera Therapeutics moved to the public markets, filing plans for an IPO to fund its obesity portfolio, led by weekly GLP-1/GIP agonist ribupatide (KAI-9531). The Boston-based biotech, backed by Bain Capital and others, said it plans to use proceeds to push ongoing clinical development through late-stage studies and regulatory review. Kailera’s lead program is in global Phase III testing (NCT07284875), and it reported 48-week Phase 3 results in China showing mean weight loss of about 18% with ribupatide. The company also has an oral ribupatide candidate and a second GLP-1 program, KAI-7535, under Phase III oversight in China. In its SEC filings, Kailera disclosed substantial accumulated deficits and warned that significant expenses and operating losses are expected for years as it completes trials and seeks approvals. The company cited competitive pressure in a market dominated by Eli Lilly’s Zepbound and Novo Nordisk’s GLP-1 portfolio. The IPO filing underscores how late-stage obesity drugs continue to attract capital—despite market volatility—because near-term regulatory milestones can quickly change valuation trajectories for high-profile runners.